Member Info for redboy33

Good afternoon,

Per the 16th March RNS the following was stated "We are also working with Prime on an application for a further block in Cameroon during the current license round, and we are continuing to work on further data acquisition on PEL96". I may have missed it not seen any updates by TRP since. I appreciate there have been blocks awarded but last I understood there were 4 (I think) that were still to be announced by the Ministry. I think there have been a few posters referencing email comms with JA that nothing decided yet and "we might not want them", but appreciate if anyone can update?

Thanks, Red

Great, then you have no need to be here then do you.

Tell me, are you in competition with Tony to see who can come with the most stupid posts?

You need to get a life. Owner of multiple properties, runs a farm but has a disabled daughter, yet spends their entire life on share forum preaching to all about everything but LLOY!

Agreed JPNEB.

In my opinion, as an investor, this is a good RNS, whereby those recognising the scale and potential of both projects will appreciate the detail provided within the RNS. Would not be surprised to see this move up in the coming days, IMO.

ATB to all investors.

Trade at 13:04 for 7,012,856 is a Buy, so assume the 10m also a Buy

Good morning,

As already mentioned, good to have an update/report, albeit still digesting.

The below caught my attention regards Namibia.

"However, the process of approving the farm-out has taken longer: the UPU has only begun its work during the past few months (since the 2025 year-end). Since then, we have had two meetings with the UPU, the most recent in mid-May 2026, and we have been told that due diligence on our partner Prime has been completed, and that approval of the farm-out has been recommended to the Minister and will be expedited."

Perhaps Friday movement due to some 'mystical foresight' that an RNS was coming without knowing the content. IMO

ATB to Investors

Good afternoon,

Well I certainly concur with CMG that we are in a quiet period! And not being the most patient (a key rule in investing) I am finding the situation frustrating, as in my opinion, the RNS did infer confirmation of either Cameroon or Namibia would have been received by now, but I will continue to hold.

I do find the trading quite interesting and I'm probably completely wrong but it just seems that regardless of a run of buys or sells (and their value) we remain in a tight range corresponding to the placing price. I think it was Monday when there was a large buy (think 180m shares) which seemed to encourage a few buys and hoped it was a turning point but unfortunately I continue to try and manage my patience.

I have shared a couple of emails with Jeremy and appreciate that he does respond which in fairness is a rare quality, but I'd also suggest that while he is probably as keen for the respective government bodies to 'deliver' he has a responsibility to perhaps be a little clearer with the RNS, which as I said and in my opinion, inferred news before now.

ATB

Red

I'm no expert on Uncrossing Trades but seemed strange that it was so much higher (price) and (from memory) small quantity. See tomorrow.

Good evening,

Logged into my Interactive Investror account and share price 0.03 (15% up), thought must be a mistake as been dead all day. Checked though on TRP and also 0.03' LSE s I type now showing 15% up but still 0.026? RNS logged?

Info. Share Post 3 of 3:

Q: On 29th March an MOU was entered into with Vatic. I suggest this point is also covered above, i.e. is this still progressing?

A: This is still in place. When there is any significant update the Company will provide it via RNS, but we would expect any update on this or the two agreements mentioned below to be included, if relevant in a post year-end trading update and in the final results. You will note that last year a year end trading update was provided mid-August and year end results announced in November.

Q: On 30th May RNS announced an agreement with DeepVerge (MOU on 29th March). It is nearly 2 months now and no update on this project? When and what will be the next stage to be announced to shareholders please?

A: The MOU has progressed to contract and the companies are working together to develop the tests as annouced in the original RNS. If there is any further update then I would expect this to be included in the trading update or year end results announcement.

Q: On 17th May RNS signed a significant (initial) 12 month contract with a leading European Customer. It is nearly 2 months now and no update? I think you may have previously commented that a general update might be provided at the end of August?

A: The signing of an agreement is the kick off to a number of work streams that predicate ABDX receiving manufacturing orders and a customer’s product going into full scale manufacturing. Once the technical transfer element of this product has completed ABDX would reasonably expect purchase orders to come into the business, at which time (depending on materiality) they would announce this to shareholders.

I would expect that the next update you will receive will be at the year-end trading update (last year was mid-August, but no date has been set for this) and I will discuss the areas you’ve mentioned above with the Executive team ahead of that. We are working with the Company to look at ways in which it can provide a greater flow of information, for example through webinars, company presentations and independent research and we will keep you updated on that as these come to fruition.

Info. Share - Post 2 of 3:

Q: Arise Corporation RNS 6th June subject to EUA approval. Novavax received Taiwan EUA for their Covid-19 vaccine in 6 weeks (announced application on 13th May - EUA receipt announced on Jun 23). Is it not reasonable to therefore assume that news on this EUA application should be weeks away rather than months? I cannot believe there is not some timeline that ABDX/Arise have in mind. I am not asking for specific dates nor would I hold ABDX accountable should any indicative timeline prove to change but to have no idea I find hard to believe (I do not mean any disrespect)?

A: ABDX is not involved with or in control of this approval process and they have not provided any guidance on when this might be concluded. You will need to make your own conclusions as to whether the timescale of one single approval is indicative of general timescale for receipt of EUA – our experience is that timescales are not uniform and vary from one application to another. It is for these reasons ABDX has not provided guidance – and I can assure you other shareholders would disagree with you and would feel they ought to be held accountable should any timescales provided to the market not turn out to be accurate.

Q: In the 2nd March Trading Update ABDX announced that Vatic had advised, “its expectation of a near-term submission to the FDA EUA. The Directors expect the Vatic Know-Now™ test to complete technical transfer to manufacture during March 2022 and the Company has received initial manufacturing orders”. 4 months have now lapsed and I understand there have been some key senior level personnel changes at Vatic in this time. Is this application progressing or has it been withdrawn? (assume the TT has been completed?).

A: I have no further information to provide you on Vatic’s FDA EUA submission – this isn’t the kind of information I can provide to shareholders individually. I will raise this point with the Company.

Q: No update on discussions with Avacta as per 2nd March Trading Update?

A: There is no update – again this would need to be something addressed in an RNS and not via email.

INFO. SHARE Post 1 of 3

Good evening,
At the weekend I sent an e mail to Walbrook to gain some clarification where possible on a number of points. For the record I have used some information from posters in some areas I have raised. Wrongly or rightly these are the points I decided to raise and just thought I would share the responses Walbrook were kind enough to share today.

ATB to all investors.


I’d be grateful for some clarification on the below please (where you are possibly able to do so):

Q: DHSC Dispute: £1.5m has been held on charge. Is it accurate to say that should the GLP lose its case against the DHSC then these monies will be payable to ABDX (albeit some of these funds may be payable to ODX etc.). If the GLP win the case then these monies (but only these monies) will be retained by DHSC?

A: As disclosed £1.5m had been held on charge until the result of the Judicial Review is known, but there has been no confirmation from the DHSC on what the implications are should the judicial review go in the favour of the GLP.

Q: Do ABDX have a policy to no longer work with DHSC in the future (various new tenders for LFTs have recently been announced).

A: ABDX does not have a policy to no longer work with the DHSC, but the Company does not take on development costs for any new tests on behalf of any customer at risk and would not normally enter into agreements of the nature of some of the DHSC COVID Antobody related contracts in normal course of business (such as the procurement contract). ABDX does not have a COVID LFT approved to be sold in the UK in any case. That said it is a contract manufacturer of LFTs for a number of partners who may wish to sell their tests in the UK or submit for these tenders.

Q: On 21st July ABDX announced the launch of the “Simply Test” e-commerce website. I assume that to agree the internal business case of this project (i.e. the cost:reward) there is some expectation of the annual revenue that is expected to be achieved?

A: Yes, the company will have made its own assumptions surrounding the long-term business case for this new product portfolio.

I agree Chris especially as this was registered on 22nd June. I like to think it is positive perhaps just for accounting purposes and SP is looking OK.
I might be interpreting incorrectly but 2nd para on page 21(25 of 27) refers to "including but not limited to interest...") sounded positive

Good morning,
I have e mailed Walbrook and will share any response, as way above my level to interpret the meaning.
Regards
Red

Good Afternoon Sledgey21,
I sent an e mail to Paul on Tuesday regards headcount and initially he confirmed 250 but then emailed back to say he would confirm with ODX.
I have sent a chaser today with your link asking for confirmation on numbers and whether the advert is for extra's (to the 250). I will share any reply from Paul.
ODX tweet of May 6th details the staff build up between the 2 sites:
Mar20 = 135
Sep20 = 144
Jan21 = 191
Apr21 = 250+
My guess would be that as they are agency/temp to perm they possibly stood staff down (i.e. had recruited to 250 but with delays by HMG reduced headcount) and now are recruiting back up to the 250 as an order/s may be imminent. Just my opinion.
ATB
Red

Guys, why don't you get outside and enjoy the weather rather than spending the afternoon just talking about it?

Good Morning JHolder,
It is my understanding it is July.
Please see below response from Walbrook on Tuesday.........."5. The Company would normally provide an update on all core product lines at the full year results which should be announced in July – they will no doubt update on Food Print then."
ATB
Red

Q3: ABC Antibody test: presume ODX are producing in quantities requested on behalf of UKRTC? Would ODX consider the outstanding payment by government of initial order (I believe in ODX case c£1.5m) to qualify for an RNS? I assume no progress on MHRA home test approval and selling on professional use only, which seems to stalled since Colin indicated that this would have been granted in September (I appreciate this was stated in the best intention at the time and not in his control)?
A3: Yes, Omega are producing AbC-19 tests for the UK-RTC as part of their build-up of stock in anticipation of orders. You can see the updates provided by ABDX on this matter. The UK Government order payment is not something that requires an RNS as it was not deemed material enough to warrant a separate announcement. We have not had any further update from ABDX on the MHRA approval process.

Q4: Food Detective (approved Nov.20’): As the approval was delayed due to Cv19 is ODX still comfortable that the target (as reported last year) of selling 1 m tests in calendar 2023 is on track?
A4: Omega hasn’t revised its views on their original 2023 target, which was based on their distribution partners view of the market – so this remains their current guidance.

Q5: Food Print is I understand a Lab based version of Food Detective aimed at the USA market. Is it possible to provide any update of how this product is performing? Even if this is to confirm it is meeting the expectations that ODX hoped for?
A5: The Company would normally provide an update on all core product lines at the full year results which should be announced in July – they will no doubt update on Food Print then.

Q6: Cryptococcus (CrAg) and TB – LAM: ODX advised in March 2020 that these 2 new products would be added to its global healthcare portfolio with a indicative time-line of- 24-30 months (cSept22’) and 36-42 months (cSept23’). I’m grateful that ODX gave indicative timelines and that with new products there are presumably many variables which could delay these but is any update available to confirm they are progressing as well as had been hoped for?
A6: I will ask the Company to also consider an update on these in their full year results – there is no meaningful update to provide on progress that would warrant a standalone announcement.

ATB

Red

Good Afternoon,
I posted last week that I had contacted Paul and would share response when received. Please find below for your information reply received this morning.

Good Afternoon Paul,
Like many investors I am increasingly concerned by the constant falling share price but more so by the absence of communication despite the numerous new product launches and would be grateful for any update/comment/response, in due course, on the points listed below:
Q1: I sent an earlier e mail asking about the UnitAid CD4 article (yesterday). Appreciate you will not have had time to respond as yet.
A1: Thank you for sending this article. It certainly looks interesting and I have passed it to the Company – I appreciate it has no direct impact on sales performance for CD4 testing at the moment, but it certainly provides additional marketing ammunition for ODX team when they engage with NGOs regarding the need and additional relevance of CD4 testing.

Q2: The Visitect Antigen test launched 30th April. Fully appreciate that this is only 2 weeks ago albeit I would expect ODX would also have been in discussions prior to this date. I also note and appreciate that the RNS was clear that updates would be provided when applicable. However could you comment on:
Q2A: Presumably the “potential commercial partners” are UK and non UK?
A2A: Omega are in conversations with but UK and non-UK commercial partners – but their main focus is to market this outside of the UK using their global distribution network.
Q2B: Is it reasonable to assume, that in part, UK commercial deals may not occur until June due to the free provision of LFTs to public and commercial sector until this time?
A2B: The fact that the UK Government is giving away free LFT antigen tests will inevitably have any impact on the UK opportunity, hence the focus on non-UK markets.
Q2C: My apologies on this question as I have probably overlooked this point. But is the Mologic Antigen LFT (TT’s and launched under Vistect by ODX in April) undergoing valuation by Porton Down/PHE on behalf of UK Govt.?
A2C: Omega is not in a position to comment on which tests may or may not be part of the performance evaluation.

Good Morning Twatcher,
I suggest that if you believe the 6th May tweet was a delaying tactic you contact ODX/Walbrook for clarification/explanation? It might have been a tweet that could have been better worded but I chose (wrongly or rightly) to interpret it to mean that news could not be given before the local elections and not necessarily at 0700 on the 7th.
I was invested in a company (UJO) that was awaiting news on their Wressle Appeal (against the N. Lincs council) but the general election (13/12/19) delayed this. The RNS advising the appeal had been won was not given until 17/01/20. I am not saying it will be c4 weeks I am just trying to give what might be considered a similar example whereby local and central governments do not work as quickly as we might like/expect and that we need to continue to be patient.
ATB
Red